Posted by Michael Wonder on 31 Aug 2022
CADTH ruling on Spinraza (nusinersen) extinguishes hope for adults needing treatment for spinal muscular atrophy
30 August 2022 - CADTH recommends against reimbursement and access to potentially life-altering treatment for adult spinal muscular atrophy patients, discounting the large body of real-world evidence of Spinraza's safety and effectiveness across age groups.
Biogen Canada is deeply saddened by the CADTH final recommendation against public reimbursement of Spinraza (nusinersen sodium) for adults with spinal muscular atrophy, and by what the decision means for this rare disease community.
